Major Step Forward in Cizzle Biotechnology's Programme with Bio-Techne
Dr. Allan Syms, Executive Chairman of Cizzle Biotechnology plc, discusses the completion of their Evaluation Programme with Bio-Techne for the CIZ1B cancer biomarker. He explains the importance of the CIZ1B biomarker in early-stage lung cancer detection, the benefits of partnering with Bio-Techne, plans to market their diagnostic solution, and his positive outlook for the company's future.
For more details, watch the full interview: Cizzle Biotechnology programme with US firm Bio-Techne takes major step forward on Vimeo.
Significant Progress in Lung Cancer Research
In a recent interview, Cizzle Biotechnology Holdings PLC highlighted a significant advancement in its collaboration with US-based firm Bio-Techne. This partnership is focused on developing and commercializing the CIZ1B biomarker test, which aims to improve early lung cancer detection.
Key Developments:
Enhanced Collaboration:
The partnership has been strengthened to accelerate the development of the CIZ1B test.
Strategic Milestones:
The collaboration is making significant progress towards clinical validation and market readiness.
Future Outlook
The strengthened partnership is set to expedite the clinical validation process, aiming for a quicker market launch. This step forward reinforces the potential of the CIZ1B biomarker test to revolutionize early lung cancer detection, making it more accessible and reliable.
Financial Implications
Cizzle Biotechnology Holdings PLC will benefit from milestone payments and royalties, indicating a robust financial outlook for the collaboration.
For more detailed information, read the full article on Cizzle Biotechnology's website: Cizzle Biotechnology Programme with Bio-Techne.
